CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its drug discovery and development programs and provide a general corporate overview at the 8th Annual BIO Investor Forum on Thursday, October 29, at 11:30 a.m. PT (2:30 p.m. ET) at the Palace Hotel in San Francisco, CA.
